Lung Cancer Clinical Trials in Philadelphia

Showing 361-363 of 363 trials

BBR 3464 in Treating Patients With Metastatic Small Cell Lung Cancer That Has Not Responded to Previous Treatment

NCT00014547

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BBR 3464 in treating patients who have metastatic small cell lung cancer that has not responded to previous treatment.

Lung Cancer

TheradexStarted Nov 2000

Hoover, Alabama, United States • Fayetteville, Arkansas, United States • Berkeley, California, United States +15 more locations

UNKNOWNPHASE251 miles

Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT00254319

Avastin is a novel antiangiogenic agent that has recently been shown to improve response rates and survival of patients with advanced nonsquamous non-small cell lung cancer when added to front-line carboplatin/paclitaxel chemotherapy, and is now being routinely incorporated into the treatment of these patients. Alimta is a recently approved chemotherapeutic that has shown activity against non-small cell lung cancer when given alone and in combination with carboplatin, has a favorable toxicity profile andrequires only a brief (10 minute) infusion time. Therefore we propose to study the combination of Avasin, Alimta, and Carboplatin administered as front-line therapy to patients with advanced nonsquamous non-small cell lung cancer.

Untreated Advanced Non-Small Cell Lung Cancer

The Cooper Health System

Voorhees Township, New Jersey, United States

BBR 3464 in Treating Patients With Metastatic Small Cell Lung Cancer That Has Not Responded to Previous Treatment

Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)

Lung Cancer Trials in Other Cities

Inhaled Doxorubicin Plus IV Docetaxel and Cisplatin in Patients With Non-Small-Cell Lung Carcinoma (NSCLC)

Other Conditions in Philadelphia